Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Clinical Usefulness of Sequential Circulating-Tumor DNA Analysis in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy

Ga-Young Song, Joo Heon Park, Seung Jung Han, Ho Cheol Jang, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Young Rok Do, Deok-Hwan Yang

Blood (2024) 144 (Supplement 1): 6221.

https://doi.org/10.1182/blood-2024-204540

Published: 2024

Journal Articles

Chromosome Abnormality Spectra and Clinical Impact in 1,787 Cases of Acute Leukemia in Koreans

Dong Geun Son, Ho Cheol Jang, Young Eun Lee, Yong Jun Choi, Joo Heon Park, Hee Jo Baek, Hoon Kook, Mihee Kim, Ga-Young Song, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim, Jae-Sook Ahn, Myung Geun Shin

Blood (2024) 144 (Supplement 1): 6097.

https://doi.org/10.1182/blood-2024-202685

Published: 2024

Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2023-184723

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

Single-Cell RNA Sequencing Identifies Distinct Immune Microenvironment in Patients with Primary Plasma Cell Leukemia

Hyunsoo Cho, Haerim Chung, Jin Seok Kim, Mihee Kim, Ga-Young Song, Seo-Yeon Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, Je-Jung Lee, Jae-Sook Ahn, Sung-Hoon Jung

Blood (2023) 142 (Supplement 1): 6583.

https://doi.org/10.1182/blood-2023-187527

Published: 2023

Journal Articles

Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: Evaluating Outcomes According to Cytogenetic Risk

Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Mi Yeon Kim, Hyeoung Joon Kim, Jae-Sook Ahn

Blood (2023) 142 (Supplement 1): 2199.

https://doi.org/10.1182/blood-2023-180464

Published: 2023

Journal Articles

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Ho Sup Lee, Dajung Kim, Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jae Hoon Lee, Won-Sik Lee, JiHyun Lee, Gyeong Won Lee, Min Kyoung Kim, Ho-Jin Shin, Hyo Jung Kim, Jun Ho Yi

Blood (2023) 142 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2023-180325

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Genetic Mutations in Primary Refractory Diffuse Large B-Cell Lymphoma: Next Generation Sequencing Analysis

Ga-Young Song, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Jae-Sook Ahn, Je-Jung Lee, Hyeoung Joon Kim, Deok-Hwan Yang

Blood (2023) 142 (Supplement 1): 6098.

https://doi.org/10.1182/blood-2023-185039

Published: 2023

Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood (2023) 142 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2023-180809

Published: 2023

Journal Articles

Bone Marrow Cellularity at Diagnosis Predicts Outcomes of Patients with Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation

Seo-Yeon Ahn, Mihee Kim, Ga-Young Song, Sung-Hoon Jung, Jae-Sook Ahn, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim

Blood (2023) 142 (Supplement 1): 7108.

https://doi.org/10.1182/blood-2023-190055

Published: 2023

Journal Articles

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

Manh-Cuong Vo, Sung-Hoon Jung, Van-Tan Nguyen, Van-Dinh-Huan Tran, Sang-Ki Kim, Woo Kyun Bae, Hyeoung-Joon Kim, Lin Wang, Je-Jung Lee

Blood (2023) 142 (Supplement 1): 6811.

https://doi.org/10.1182/blood-2023-188428

Published: 2023

Journal Articles

Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine

Mihee Kim, Taehyung Simon Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, MiYeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Kim

Blood (2022) 140 (Supplement 1): 6094–6095.

https://doi.org/10.1182/blood-2022-164916

Published: 2022

Journal Articles

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Blood (2022) 140 (Supplement 1): 1018–1019.

https://doi.org/10.1182/blood-2022-166182

Published: 2022

Journal Articles

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Ji Yun Lee, Soo-Mee Bang, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Lee Gyeong-Won, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Je-Jung Lee, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Min Kyoung Kim

Blood (2022) 140 (Supplement 1): 12501–12502.

https://doi.org/10.1182/blood-2022-165807

Published: 2022

Journal Articles

Prognostic Significance of 18 f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma

Ga-Young Song, Sung-Hoon Jung, Seo-Yeon Ahn, Mihee Kim, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Su Woong Yoo, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Sae-Ryung Kang, Deok-Hwan Yang

Blood (2022) 140 (Supplement 1): 9571–9572.

https://doi.org/10.1182/blood-2022-168531

Published: 2022

Journal Articles

Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment

Mihee Kim, Taehyung Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, MiYeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim

Blood (2021) 138 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2021-152316

Published: 2021

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2021-146974

Published: 2021

Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2021-148937

Published: 2021

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

NARROW

Clinical Usefulness of Sequential Circulating-Tumor DNA Analysis in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy

Chromosome Abnormality Spectra and Clinical Impact in 1,787 Cases of Acute Leukemia in Koreans

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Single-Cell RNA Sequencing Identifies Distinct Immune Microenvironment in Patients with Primary Plasma Cell Leukemia

Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: Evaluating Outcomes According to Cytogenetic Risk

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Genetic Mutations in Primary Refractory Diffuse Large B-Cell Lymphoma: Next Generation Sequencing Analysis

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Bone Marrow Cellularity at Diagnosis Predicts Outcomes of Patients with Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Prognostic Significance of 18 f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma

Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only